Termination of the business combination with Second Sight Medical Products, Inc.

Written by Customer Service on April 2, 2021. Posted in Public Companies.

Termination of the business combination withSecond Sight Medical Products, Inc. Paris, France, April 3, 2021 – Considering the private placement recently announced and closed by Second Sight Medical Products, Inc. (“Second Sight”) was not only explicitly prohibited under the terms of the memorandum of understanding (“MOU”) entered into by the companies on January 5, 20211 but also detrimental to Pixium Vision’s interests, the company has offered Second Sight to renegotiate the MOU in order to allow the pursuit of the business combination while preserving the contractual balance and the interests of Pixium Vision and its shareholders. Pixium Vision regrets that Second Sight never responded to the proposals it made in good faith nor demonstrated any willingness to reach such agreement. Following this delaying attitude and refusal to enter...

Abandon du rapprochement avec Second Sight Medical Products, Inc.

Written by Customer Service on April 2, 2021. Posted in Public Companies.

Abandon du rapprochement avecSecond Sight Medical Products, Inc. Paris, France, 3 avril 2021 – Compte-tenu de l’augmentation de capital réalisée récemment par Second Sight Medical Products, Inc. (« Second Sight ») en violation du protocole d’accord conclu le 5 janvier 20211 et qui porte atteinte aux intérêts de Pixium Vision, cette dernière a proposé à Second Sight de renégocier le protocole d’accord afin de permettre la poursuite du projet rapprochement tout en préservant l’équilibre contractuel initial ainsi que les intérêts de Pixium Vision et de ses actionnaires. Pixium Vision regrette que Second Sight n’ait jamais répondu aux propositions qu’elle a faites, de bonne foi, ni démontré une quelconque volonté de parvenir à un tel accord. Persévérant dans une attitude dilatoire et refusant d’entamer des discussions avec la société, Second...

Termination of the business combination with Second Sight Medical Products, Inc.

Written by Customer Service on April 2, 2021. Posted in Public Companies.

Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

Written by Customer Service on April 2, 2021. Posted in Public Companies.

Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade Supernus plans to make Qelbree available in the U.S. in 2Q 2021 ROCKVILLE, Md., April 02, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) approved Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age. “Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD,” said Jack A. Khattar, President and Chief Executive...

DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors

Written by Customer Service on April 2, 2021. Posted in Public Companies.

Montrouge, France, April 2, 2021DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today the provisional appointment of Mr. Timothy E. Morris, as director, by the DBV Board of Directors, effective March 30, 2021. Mr. Morris will serve as a member of the Audit Committee of the Board. With this addition, the Board comprises nine directors. “We are pleased to welcome Tim Morris as a new director to the DBV Board,” said Michel de Rosen, Chairman of DBV Technologies’ Board of Directors. “Tim brings to DBV more than 20 years of leadership experience in the biopharma sector and he is highly regarded for his finance and commercial capabilities. We believe he will add tremendous...

DBV Technologies annonce la nomination de Timothy E. Morris au conseil d’administration

Written by Customer Service on April 2, 2021. Posted in Public Companies.

Montrouge, France, 2 avril (22 h 30 CEST), 2021DBV Technologies annonce la nomination de Timothy E. Morris au conseil d’administration DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), une société biopharmaceutique au stade clinique, a annoncé aujourd’hui la nomination provisoire de M. Timothy E. Morris en tant qu’administrateur, par le conseil d’administration de DBV, à compter du 30 mars 2021. M. Morris sera membre du comité d’audit du conseil d’administration. Avec l’arrivée de M. Morris, le conseil d’administration sera composé de neuf administrateurs. « Nous sommes heureux d’accueillir Tim Morris en tant que nouvel administrateur au sein du conseil d’administration de DBV », a déclaré Michel de Rosen, président du conseil d’administration de DBV Technologies....

ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

Written by Customer Service on April 2, 2021. Posted in Public Companies.

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation at the Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) held April 9-11, 2021. ProQR’s presentation Presentation title: A different type of genetic therapy: correcting a defective gene using antisense oligonucleotide treatment in CEP290 p.Cys998X LCAPresenter: Arlene V. Drack, MD, Ronald Keech Professor of Pediatric Genetic Eye Disease Department of Ophthalmology and Visual Sciences, University of IowaPresentation type: Oral paper presentationDate: April 10, 2021 at 1:23pm EDT. The presentation will be available...

Cytokinetics Announces Preclinical Data for CK-3773274 to be Presented at the American Chemical Society Spring 2021 Virtual Meeting

Written by Customer Service on April 2, 2021. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., April 02, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to CK-3773274 (CK-274), including data regarding its discovery and key optimization parameters, will be presented at the American Chemical Society Spring 2021 Virtual Meeting, taking place online from April 5, 2021 to April 30, 2021. Session Title: First Time DisclosuresPresentation Title: Discovery of CK-274: A novel, small molecule, cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathies (HCM)Presenter: Grace (Chihyuan) Chuang, Ph.D., Director, Medicinal Chemistry, CytokineticsDate: Friday, April 9, 2021Time: 11:05 AM – 11:45 AM PT About Cytokinetics Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class...

First Hawaiian to Report First Quarter 2021 Financial Results on April 23

Written by Customer Service on April 2, 2021. Posted in Public Companies.

HONOLULU, April 02, 2021 (GLOBE NEWSWIRE) — First Hawaiian, Inc. (NASDAQ: FHB) announced today that it plans to release its first quarter 2021 financial results on Friday, April 23, 2021 before the market opens. First Hawaiian will host a conference call to discuss the company’s results on the same day at 1:00 p.m. Eastern Time (7:00 a.m. Hawaii Time). To access the call, participants should dial (844) 452-2942 (US/Canada), or (574) 990-9846 (International) ten minutes prior to the start of the call and enter the conference ID: 4277629. A live webcast of the conference call, including a slide presentation, will be available at the following link: www.fhb.com/earnings. The archive of the webcast will be available at the same location. A telephonic replay of the conference call will be available approximately two hours after...

Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings

Written by Customer Service on April 2, 2021. Posted in Public Companies.

Basking Ridge, NJ, April 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Timber Pharmaceuticals, Inc. (NYSE American: TMBR) (“Timber” or the “Company”), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that its Annual Meeting of Shareholders will be held at 1:00 pm EDT on Thursday, June 3, 2021 (the “Annual Meeting”). The Company has established April 12, 2021 as the record date for the Annual Meeting. Meeting materials with details on the location of the Annual Meeting will be mailed to shareholders on or about April 23, 2021. The Company also advised that its audited consolidated financial statements for the fiscal year ended December 31, 2020, included in the Company’s Annual Form on Form 10-K, contained...

Day: April 2, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice